Thomas Hogan, MD

Professor

Organization:

West Virginia University WVU Cancer Institute

Department:

Department of Medical Oncology

Classification:

Faculty

• MD, Medical College of Virginia, Richmond, VA

Ten Most Recent:

Audit of the current drug shortage situation.
Higa GM, Ghani N, Gianni M, Hogan TF.
WV Med J. 2013;109(5):18-20.

Survival disparities in bladder, kidney, and prostate cancer in Asian-Indian & Pakistani immigrants to the United States as compared to other US ethnic groups: a Surveillance, Epidemiology and End Results (SEER) 2011 public use database study.
Hossain A, Hogan TF, Rahman R, Hobbs GR.
Cancer and Clinical Oncology. 2013;2(1):103-114.

Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
Hogan TF, Jing JY, Williams HJ, Altaha R, Xiaobing L, Qi H.
J Oncol Pharm Pract. 2009;15(2):111-117.

Cisplatin, gemcitabine and paclitaxel triplet chemotherapy in 50 patients with advanced or metastatic urothelial cancer.
Hogan TF, Lamm DL, Schuun GB, Hernadez JL, Kandzari SJ.
WV Med J. 2006;102(2):12-15.

Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Jr., Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL.
J Clin Oncol. 2006;24(7):1079-1089.

Integrative tumor board: Transitional Cell carcinoma of the bladder.
Lamm DL, Hogan TF.
Integr Cancer Ther. 2005;4(1):48-64.

A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination.
Riley RS, Hogan TF, Pavot DR, Forysthe R, Massey D, Smith E, Wright L, Jr., Ben-Ezra JM.
J Clin Lab Anal. 2004;18(2):70-90.

Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia: a case report and review of the literature.
Kurian S, Hogan TF, Bleigh OC, Dowdy YG, Merghoub T, Pandolfi PP, Wenger SL.
Cancer Genet Cytogenet. 2002;138(2):143-148.

Smoking and renal cell carcinoma.
Hogan TF, Lamm DL, Ducatman AM.
WV Med J. 2001;97(1):32-35.

Smoking and bladder cancer.
Hogan TF, Lamm DL, Riggs DR, Ducatman AM.
WV Med J. 2001;97(1):29-31.
 

HONORS-AWARDS

1964            National Merit Scholarship Finalist

1968            BS Magna cum Laude, Roanoke College

1972            AOA Medical College of Virginia

1976-79       National Research Service Award

1977-79       American Cancer Society, Post-doctoral fellow

1984-86       Continuing Education Faculty Award, WVU, Charleston,WV

1994-95       Resident Liaison, ASCP

1999            Distinguished Teacher Nomination, WVU SOM

1999            National Registry of Who's Who

2001            West Virginia University Hospital Team Quality Award

2005-14       Best Doctors in America

2008-12       Who’s Who, Marquis

2009-16       America’s Top Doctors for Cancer, Castle Connolly

2012            US News High Performing Physician, Top 1%

2013            Irish Voice, Irish Education 100

2013-14      Press Ganey Top Provider

2015            WVUH Excellence in Patient Care, Supportive Care Team

2015            Newsweek “Top Doctors for Cancer”  

2015-16      Monongalia County Medical Society, President

PROFESSIONAL MEMBERSHIPS AND SOCIETIES

Alliance Oncology Group (ECOG) 1982-2016

American Association for Cancer Research, 1981-2016

American College of Surgeons Oncology Group, 2002-2011

American Society of Clinical Oncology, 1981-2016

Association of Community Cancer Centers 2013-2015

Monongalia County Medical Society 1982-2016

Mary Babb Randolph Cancer Center 2011-2016

West Virginia Oncology Society 2009-2016

West Virginia State Medical Society 1982-2016

Dr. Thomas Francis Hogan is currently a Professor in the Section of Hematology-Oncology in the Department of Medicine at West Virginia University. He graduated from The Medical College of Virginia (Virginia Commonwealth University), Richmond, and had his residency in Internal Medicine at Thomas Jefferson University, Philadelphia. He also completed a residency in Anatomic Pathology at West Virginia University, Morgantown, and completed a fellowship in Medical Oncology at the University of Wisconsin, Madison. After serving for a few years at the Marshfield Clinic, Wisconsin, then at the Mayo Clinic, Phoenix, he rejoined the faculty at the School of Medicine at WVU in 2005.  He served as the Director of the WVU Hematology-Oncology Fellowship for ten years, and currently focuses his clinical practice to Genito-Urinary Oncology (cancer of the adrenals, kidneys, bladder and ureters, testicles) as a member of WVU Healthcare’s nationally recognized, multidisciplinary GU-Oncology program.

Dr. Hogan has recently served on a Bristol Myers Squibb Patient Data Monitoring Committee, and as a national CARIS Precision Oncology Associate (Genitourinary Group). His interests include molecular studies on urologic tumors, and development of clinical studies for the Chinese antineoplastic drug dicycloplatin. In recent years, He has been acknowledged by Marquis Who’s Who in the world, Castle Connolly America’s Top Doctors for Cancer, US News High Performing Top 1% Physician, the Irish Voice Irish Education 100, a Press Ganey Top Provider, Newsweek’s “Top Doctors for Cancer”, and Dr. Hogan is a former president of the Monongalia County Medical Society.

Non-Programmatically Aligned Cancer Center Members

2004: MCS IRB 797-04: A randomized, phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advance renal carcinoma.

2005: Effect of CK3 on Prostate Cancer in Patients on Intermittent Hormone Therapy: A Phase 2 Randomized, Multi-center Study.  IND 69,304.

200x-07: Pfizer: Efficacy evaluation of SU011248 alone and in combination therapy with interferon alfa as first line for metastatic renal cell cancer.

2006-10: ECOG 9802 A Phase II Study of PROSTAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM with GM-CSF in Patients with PSA Progression after Local Therapy for Prostate Cancer.

2009: E2805 A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients with Resected Renal Cell Carcinoma

2010: E1808 (open): A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features- Version 03 Nov  2010 IRB No.: 22987

 

2010: WVU-MBRCC (submitted) Pilot study of AF1q gene amplification in prostate cancer (PC) tissue from men with PC, comparing AF1q expression to Gleason score & clinical outcomes. Livengood R, Tse W, Wenger S, Nagaiah G, Troung S, Hogan T.

2011: Takeda-Millennium C21004.  A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Protocol Version 21 July 2010

2012: WVU-MBRCC (active) MTHFR (methylene-tetrahydrofolate-reductase) mutations in an Appalachian population: mutation prevalence and potential significance

Hogan T, Khimani F, Perrotta L, Hobbs G

 

2012: ECOG 4805 (submitted). A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma. (NSC 724770, IND 100137)

 

2013: CALGB 90601 (closed to accrual) A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advance transitional cell carcinoma. (NSC 704865, IND 7921)

 

2013: ECOG1808 - A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features Thomas Hogan, MD; Carla Ross, RN

 

2015: NRG Oncology GU001 Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer. Malcolm Mattes, MD.

 

2015: RX-0201-P2-A09 Rexahn Pharma. A Multicenter Open Label Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus to Treat Subjects with Advanced Renal Cell Carcinoma. Thomas Hogan, MD

 

2015: SP005 Sotio Pharma. Phase III study to evaluate efficacy & safety of DCVAC/Pca vs. placebo in men with metastatic castration resistant prostate cancer eligible for 1^st line chemotherapy. Thomas Hogan MD

Medical Specialties

• Cancer / Oncology
• Medical Oncology (Cancer)

Board Certifications

• Anatomic Pathology, American Board of Pathology
• Internal Medicine, American Board of Internal Medicine
• Medical Oncology, American Board of Internal Medicine

Special Training

• Residency, Anatomic Pathology Resident
  West Virginia University Hospitals, 1996
• Fellowship, Medical Oncology Fellow
  Wisconsin Comprehensive Cancer Center, 1979
• Residency, Internal Medicine Resident
  Thomas Jefferson University Hospitals, 1975